Drug intelligence / Profile preview

liposomal irinotecan + apatinib

Development stage: Phase 2
Lead developer: Ipsen
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Oral

Overview

A combination therapy consisting of liposomal irinotecan and apatinib. Liposomal irinotecan is a formulation of irinotecan encapsulated in liposomes that enhances drug delivery to tumor sites through enhanced permeability and retention (EPR) effects. Apatinib is a selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor that inhibits tumor angiogenesis. This combination has been investigated in clinical trials for various advanced solid tumors, often in combination with immunotherapy (camrelizumab) and radiotherapy.

Other names: irinotecan liposomal + apatinib

Targets

TOP1 (DNA Topoisomerase I)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on liposomal irinotecan + apatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on liposomal irinotecan + apatinib.